(Q39134511)

9 September 2017

title

Downregulation of Stat3 in melanoma: reprogramming the immune microenvironment as an anticancer therapeutic strategy (English)

1 reference

9 September 2017

6

1 reference

9 September 2017

P U Emeagi

1

1 reference

9 September 2017

S Maenhout

2

1 reference

9 September 2017

N Dang

3

1 reference

9 September 2017

C Heirman

4

1 reference

9 September 2017

K Thielemans

5

1 reference

9 September 2017

publication date

27 June 2013

1 reference

9 September 2017

1 reference

9 September 2017

volume

20

1 reference

9 September 2017

issue

11

1 reference

9 September 2017

page(s)

1085-1092

1 reference

https://scigraph.springernature.com/pub.10.1038/gt.2013.35

9 September 2017

exact match

0 references

cites work

Systematic review of medical treatment in melanoma: current status and future prospects.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

STAT3 signaling: anticancer strategies and challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in human cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

Proinflammatory characteristics of SMAC/DIABLO-induced cell death in antitumor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

Intratumoral delivery and suppression of prostate tumor growth by attenuated Salmonella enterica serovar typhimurium carrying plasmid-based small interfering RNAs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

Lentivirus-mediated shRNA interference targeting STAT3 inhibits human pancreatic cancer cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

STAT3 Knockdown in B16 Melanoma by siRNA Lipopolyplexes Induces Bystander Immune Response In Vitro and In Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

Enhancement of cancer vaccine therapy by systemic delivery of a tumor-targeting Salmonella-based STAT3 shRNA suppresses the growth of established melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

Emodin and DHA potently increase arsenic trioxide interferon-alpha-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

Predicting siRNA efficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

Stat3 as a potential target for cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

Restoration of tumor equilibrium after immunotherapy for advanced melanoma: three illustrative cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

7 January 2021

STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

7 January 2021

Targeting STAT3 in cancer: how successful are we?

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

7 January 2021

Activation of Immature Monocyte-Derived Dendritic Cells After Transduction with High Doses of Lentiviral Vectors

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

7 January 2021

Lentivirally transduced dendritic cells as a tool for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.35

7 January 2021

Identifiers

DOI

10.1038/GT.2013.35

1 reference

9 September 2017

1 reference